Acrux partially sold from Growth Portfolio
Recommendation
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
Acrux's share price has risen 134% since we upgraded the stock just seven weeks ago in Ignore the FDA and buy Acrux on 13 Jun 14 (Speculative Buy – $0.80). Better yet, this capital gain is tax exempt due to Acrux's Pooled Development Fund status. The price rise has been driven by a slight improvement in valuation, accompanied by a rapid shift in market perception (see Acrux sales impress on 25 Jul 14 (Hold – $1.285)). Though the company could potentially be worth significantly more than today's price, it requires an increasingly large leap of faith and we recommend gradually taking profits as the share price rises. This allows investors to benefit if things go to plan, while ensuring they still take home a decent profit should the investment turn sour. There are still several risks, making it particularly important to adhere to our recommended portfolio limit of 2%. The stock is up 46% since 25 Jul 14 (Hold – $1.285). HOLD
Note: We're selling half our Acrux position, 3,125 shares, from the model Growth Portfolio at $1.87, for a total consideration of $5,844.
Recommendation
Call 1300 880 160
Start a chat
Schedule a call
